Studies of Dietary restriction in people
539 studies gave Dietary restriction to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases TNF-alpha down: Decreases malondialdehyde | Randomized trial12 weeks | 60 peopleadultsObesity | Metabolites, Nov 12, 2026 |
down: Decreases total and regional fat mass down: Decreases fasting insulin | Trial12 weeks | 26 peopleWomen42.9 ± 5.9 years, range: 32.7–54.5 yearsMidlife adults; overweight or obesity | Frontiers in nutrition, Nov 12, 2026 |
down: Decreases visceral fat volumeVisceral fat: 15.0% versus approximately 9.1% reduction; subcutaneous fat: 18.6% versus approximately 9.2% reduction | Randomized trial6 weeks | 20 peopleBothmiddle-agedMidlife adults | Lasers in medical science, Nov 4, 2026 |
| Trial24 months | 26 peopleadultsNon-obese adults | medRxiv, Nov 2, 2026 | |
down: Decreases kynurenine up: Increases exercise-induced kynurenic acid response | Trial12 weeks | 21 peopleWomenolderOlder adults; resting concentrations | Journal of translational medicine, Nov 2, 2026 |
down: Decreases body weight | Randomized trial12 weeks | 60 peopleMenSedentary men with overweight or obesity | Obesity pillars, Nov 1, 2026 |
down: Decreases body weight-2.7 kg (95% CI -2.9 to -2.4) down: Decreases blood pressure down: Decreases mean glucose | Randomized trial4 weeks | 68 peopleWomenadultsAcross the 16:8 and 5:2 groups with overweight or obesity | Obesity (Silver Spring, Md.), Oct 28, 2026 |
no change: Has no effect on intrahepatic fat fraction−0.4 percentage points versus usual care; 95% CI −2.0 to 1.2; P = 0.93 | Randomized trial12 weeks | 187 peopleBothadultsObesity | Nature communications, Oct 14, 2026 |
up: Improves metabolic parametersmean weight loss of ≈10% down: Decreases oxidative stress and ROS signaling down: Decreases NLRP3 expression | Trial24-week | 45 people33 females (73.3%) and 12 males (26.7%)mean age of 46.2 ± 8.7 yearsAdults with obesity | iScience, Oct 5, 2026 |
down: Decreases body weight down: Decreases HOMA-IR down: Decreases C-reactive protein | Trial20 weeks | 36 peoplewomenbetween 19 and 40 yearsWomen with polycystic ovary syndrome and insulin resistance | Research Square, Oct 4, 2026 |
down: Decreases body weightDiC − 3·36 kg, 95 % CI − 5·84 to −0·87 down: Decreases fat massDiC − 1·53 kg, −2·86 to −0·19 down: Decreases visceral fat areaDiC − 12·82 cm, −20·16 to −5·48 | Randomized trial7 weeks | 131 peoplewomenaged 18–45 yearsWomen aged 18–45 years with a BMI ≥ 27 kg/m and the ability to walk on a treadmill or ride a bicycle for at least 60 min | The British journal of nutrition, Sep 25, 2026 |
down: Decreases body weight-3.50 kg ± 2.9 no change: Has no effect on thyroid function | Randomized trial6 weeks | 39 people35.9% malemean age 56.3 yearsParticipants with previously diagnosed T2DM, body mass index (BMI) ≥ 25 kg/m2, and hemoglobin A1c between 5.5% and 9.0% | Journal of the Endocrine Society, Sep 23, 2026 |
down: Decreases body weightWMD −1.64 kg, 95% CI −2.49 to −0.79 down: Decreases fat massWMD −1.30 kg, 95% CI −1.72 to −0.89 down: Decreases waist circumferenceWMD −1.53 cm, 95% CI −2.61 to −0.44 | Review of trials | 602 people pooledPatient cohorts | Nutrition reviews, Sep 15, 2026 |
down: Decreases total cholesterol down: Decreases triglyceride | Randomized trial12 weeks | 24 peoplePatient cohorts | Research Square, Sep 10, 2026 |
down: Decreases body weight−6.83 ± 4.26 kg (−7.02%) down: Decreases body fat mass−5.38 ± 3.13 kg (−13.61%) down: Decreases soft lean mass−1.44 ± 1.88 kg (−2.68%) | Trial62-day | 35 people20 males (57.10%) and 15 females (42.90%)average age of 36.23 ± 8.98 yearsIndividuals with obesity in China | Frontiers in nutrition, Sep 9, 2026 |
down: Decreases glucose-7 ± 3 mg/dL down: Decreases HbA1c-0.2 ± 0.1% up: Improves glycemic control+3.2 ± 1.6% | Trial6-week | 15 peoplemean age of 62 ± 9 yearsIn veterans with spinal cord injury and obesity | Nutrients, Aug 29, 2026 |
down: Decreases predicted 10-year MACE risk−0.2 pp, p < 0.001 down: Decreases predicted 10-year type 2 diabetes risk−5.2 pp, p < 0.001 | Randomized trial1 year | 221 peoplepremenopausal women21-49 yearsPremenopausal women with overweight | Obesity (Silver Spring, Md.), Aug 23, 2026 |
no change: Has no effect on thigh muscle area no change: Has no effect on intermuscular adipose tissue | Randomized triala month-long | 66 peopleGeneral population | Clinical radiology, Aug 22, 2026 |
down: Decreases body mass | Randomized trial4 weeks | 80 peopleMenyoung adultAlternate-day fasting protocol | Preprints.org, Aug 19, 2026 |
no change: Has no effect on cumulative live birthaRR 0.936; 95% CI 0.676–1.295; P = 0.689 | Randomized trial | 273 peopleWomen20–38 yearsWomen with overweight or obesity planning IVF | Reproductive biology and endocrinology : RB&E, Aug 19, 2026 |
up: Increases time in range92.4 ± 5% versus 81.4 ± 6.5%; p = 0.001 | Randomized trial | 51 people25–55 yearsMidlife adults; Type 2 diabetes of ≤5 years | Diabetology & metabolic syndrome, Aug 13, 2026 |
down: Decreases eating window9.2 ± 1.4 h vs 13.3 ± 1.5 h no change: Has no effect on frailtyp > 0.05 no change: Has no effect on fatiguep > 0.05 | Randomized trial12 weeks | 24 peopleBoth68.8 ± 6.4 yearsOlder adults; cancer receiving systemic therapy | Journal of geriatric oncology, Aug 8, 2026 |
down: Decreases glucose4.7 mmol/L to 4.0 mmol/L down: Decreases IGF-123 nmol/L to 17.9 nmol/L up: Increases ketonenear zero to median 1.86 mmol/L | Trialtwo cycles of a 4-day FMD separated by 3 weeks of regular diet | 9 peopleHealthy volunteers | Nutrients, Aug 3, 2026 |
down: Decreases left ventricular massmean difference, -5.47 g up: Improves early-to-late peak filling ratiomean difference, 0.27 up: Improves mitral annular early peak velocitymean difference, 0.84 cm/sec | Randomized trial6 months | 82 peopleBothmean age, 62.9 years ± 8.5Older adults; in individuals with type 2 diabetes | Radiology. Cardiothoracic imaging, Jul 30, 2026 |
no change: Has no effect on working memory no change: Has no effect on attentional control down: Decreases body mass index | Randomized trial4 weeks | 23 peopleWomenadult | Acta psychologica, Jul 28, 2026 |
down: Decreases body weightMD = -2.32 kg, 95% CI: -2.99 to -1.65 down: Decreases HbA1cMD = -0.55, 95% CI: -0.77 to -0.33 down: Decreases body weight | Review of trials | 805 people pooledOverweight or obese adults with type 2 diabetes | Frontiers in nutrition, Jul 15, 2026 |
up: Increases high molecular weight adiponectin down: Decreases ceramide | Randomized trial2-year period | 191 peopleBothaged 21 to 50 yearsHealthy, non-obese (BMI 22–27.9 kg/m2) men and premenopausal women | Nature communications, Jul 9, 2026 |
up: Increases DTI-ALPS index down: Decreases gBOLD/CSF coupling | Trial1 month | MenIn metabolic syndrome | Journal of Alzheimer's disease : JAD, Jul 8, 2026 |
no change: Has no effect on hepatic fat fractionmean difference -0.4%, 95% CI -2.3 to 1.5 down: Decreases hepatic fat fractionmean change -1.2%, 95% CI -2.2 to -0.2 | Randomized trial12 weeks | 197 people98 womenaged 30–60 yearsWhite European adults from Spain with overweight or obesity and abdominal obesity | JHEP reports : innovation in hepatology, Jul 7, 2026 |
no change: Has no effect on resting energy expenditure no change: Has no effect on resting energy expenditure | Randomized trial3 months | 102 peopleBoth18 to 65 yearsMidlife adults; Patient cohorts | Nutrients, Jun 24, 2026 |
down: Decreases HbA1c down: Decreases nighttime glucose up: Improves time in range | Treated cohort3 months | 3 people43, 54, 61 yearsAdults with T2DM | Frontiers in clinical diabetes and healthcare, Jun 23, 2026 |
down: Decreases body weight | Randomized trial10 days | 97 peoplewomenmean age 60.6 ± 6.87 yearsCaucasian postmenopausal women with obesity and knee osteoarthritis | medRxiv, Jun 11, 2026 |
down: Decreases fat mass up: Increases fat-free mass | Randomized trial12-week dietary intervention | 30 peopleadult femalesbetween 18 and 65 years of ageAdult females | Nutrients, Jun 5, 2026 |
down: Decreases HbA1c-0.46% [95% CI, -0.80, -0.12], P = 0.01 no change: Has no effect on body weight-2.19% [95% CI, -5.70, -1.31] no change: Has no effect on body weight-0.47% [95% CI, -4.72, 3.78] | Randomized trial6 months | 32 peopleBoth41 [15] yearsMidlife adults; Patient cohorts | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
down: Decreases diabetes medication burden67% up: Increases type 2 diabetes remission14% | Randomized trial12 months | 57 peoplePatient cohorts | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
down: Decreases body weight down: Decreases fat mass down: Decreases fat-free mass | Review of trials | 1,833 people pooled<30 yearsGeneral population; Midlife adults | Nutrients, Jun 3, 2026 |
down: Decreases adaptive thermogenesis−13 ± 160 kcal vs. −83 ± 150 kcal, p = 0.038 no change: Has no effect on resting metabolic rateβ_group = 47 ± 32 kcal/day down: Decreases hunger−14 cm*min vs. 24 cm*min, p = 0.048 | Randomized trial7 d | 100 peoplemean age ~33 yearsAdults with severe obesity | Journal of human nutrition and dietetics : the official journal of the British Dietetic Association, Jun 1, 2026 |
down: Decreases body weight−1.8 kg vs 0.05 kg no change: Has no effect on acute kidney injury incidence down: Decreases inflammatory factors | Trialseven days before donation | 12 people50% male in the control group and 60% male in the CR groupmean age 52 yearsPatients scheduled for living kidney transplantation | npj aging, May 28, 2026 |
down: Decreases body weight down: Decreases energy intake−235 kcal; 95% CI: −356, −114 up: Improves diet quality | Randomized trial12 months | 220 peopleBoth38.1±7.2 years oldHealthy individuals with normal weight or overweight | Critical reviews in food science and nutrition, May 22, 2026 |
down: Decreases body weight up: Increases dietary restraint down: Decreases disinhibition | Randomized trial2 and 6 months | 209 peopleBoth58 ± 10 yearsMidlife adults; Older adults; Adults with obesity | Clinical nutrition (Edinburgh, Scotland), May 15, 2026 |